Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.80, $0.23 better than the analyst estimate of $4.57. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.05 billion.

GUIDANCE:

Vertex Pharma sees FY2025 revenue of $11.9-12 billion, versus the consensus of $12.002 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.